Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing
Executive Summary
Advisory committee supports further research on end-of-induction response as an early interim clinical endpoint for drugs in treatment of high-risk neuroblastoma. FDA has approved two drugs for this rare disease in children, who have a 40-50% chance of long-term survival.
You may also be interested in...
ODAC Applauds Effort, But Votes Against Y-mAbs’ I-Omburtamab In Neuroblastoma
US FDA advisory committee voted unanimously that there was not enough evidence to show the monoclonal antibody improves overall survival, but panelists are hopeful that real-world evidence could eventually get the orphan candidate over the finish line.
Y-mAbs’ External Control Problems May Sink Neuroblastoma Candidate I-Omburtamab
In advisory committee briefing documents, the US FDA said control data was not comparable to the single-arm trial and the benefits of the monoclonal antibody were unclear.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.